"rationale","id","instanceType","uuid:ID","versionIdentifier"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","StudyVersion","dc88fd0d-3595-4f60-9454-bf6dfc132474","2"
